MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment	Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Memory Disorders, Mild Cognitive Impairment, Neurobehavioral Manifestations, Neuroinflammatory Diseases, Neurologic Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, encephalitis, hereditary disease, inherited neurodegenerative disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Not yet recruiting	Phase 2	2025-05-18		NCT06177028

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
St. Joseph's Hospital and Medical Center, Phoenix	13
Texas Tech University	18

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.